743 The majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS®] sustain responses 2 years post-treatment
- 1 April 2006
- journal article
- abstracts
- Published by Elsevier in Journal of Hepatology
- Vol. 44, S275
- https://doi.org/10.1016/s0168-8278(06)80744-0
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: